Stem cell therapy offers hope for children with butterfly skin

NCT ID NCT05464381

Ongoing Disease control Sponsor: RHEACELL GmbH & Co. KG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a stem cell treatment for epidermolysis bullosa, a rare disease causing fragile skin that blisters easily. About 91 people with two types of EB will receive the cells or a placebo through an IV. The main goal is to see if the treatment can safely close stubborn wounds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

epidermolysis bullosa junctional epidermolysis bullosa recessive dystrophic epidermolysis bullosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDERMOLYSIS BULLOSA

Contacts and locations

Locations

Andreas Syggros Hospital of Cutaneous Venereal Diseases

Athens, Greece
Centro Hospitalar e Universitario de Comibra HUC

Coimbra, Portugal
Department of Dermatology, National Cheng Kung University

Tainan, Taiwan
EB-Haus Austria; Salzburger Landeskliniken (SALK)

Salzburg, 5020, Austria
Fundacion Debra Chile

Santiago, Chile
Great Ormond Street Hospital (GOSH)

London, United Kingdom
Hospital La Paz

Madrid, Spain
Hospital Necker-Enfants Malades

Paris, France
Medical Concierge Centrum Medyczne

Warsaw, Poland
Ospedale Pediatrico Bambin Gesu

Roma, Italy
Sanatorio Mater Dei

Buenos Aires, Argentina
Semmelweis Egyetem

Budapest, Hungary
Service de Dermatologie Hospital Saint-Louis

Paris, France
UOSD Pediatria-Alta Intensita di Curà, Ospedale Maggiore

Milan, Italy
Universitaetsklinik fuer Dermatologie und Allergologie

Nice, France
Venereal & Skin Diseases Hospital of Thessaloniki

Thessaloniki, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.